Artiva Biotherapeutics (ARTV) Projected to Post Earnings on Tuesday

Artiva Biotherapeutics (NASDAQ:ARTV) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.72) per share for the quarter.

Artiva Biotherapeutics Stock Up 5.1 %

Shares of ARTV stock opened at $5.36 on Monday. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31. The company has a 50-day simple moving average of $6.06 and a two-hundred day simple moving average of $9.88.

Analyst Upgrades and Downgrades

ARTV has been the subject of several recent analyst reports. HC Wainwright assumed coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $21.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.